ReviewTranslational research : the journal of laboratory and clinical medicine2021
Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier.
Review in Translational research : the journal of laboratory and clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 52 citations in OpenAlex.
- Immune dysregulation and gut microbiota: Connection to health and disease development.Neural regeneration research · 2026Article
- Lactobacillus plantarum Attenuates Intestinal Inflammation and Prolongs Remission in Experimental Models of Crohn's Disease.Probiotics and antimicrobial proteins · 2026Article
- Glycocholic acid inhibits TRIB3-ID1 axis to acelerate colitis progression via suppressing intestinal stem cell renewal.Nature communications · 2026Article
- Review
- A polymer that reinforces luminal barrier function and attenuates inflammation in murine colitis.Research square · 2026Article
- Human colon organoid Transwell model for investigating epithelial growth and repair.npj biomedical innovations · 2026Article
- OTOP2 proton channel couples luminal pH sensing to intestinal immune homeostasis.The Journal of biological chemistry · 2026Article
- Colonic epithelial regeneration shapes susceptibility tobioRxiv : the preprint server for biology · 2026Article
- The impact of noninfective enteritis and colitis on outcomes following shoulder arthroplasty: a propensity-matched retrospective cohort study of 8,574 patients.JSES international · 2026Article
- α-Hemolytic Streptococcus-Derived Mannatide Attenuated DSS-Induced Colitis in Mice Via Reducing Inflammation, Immunomodulatory, and Mucosal Protective Effects.Probiotics and antimicrobial proteins · 2026Article
- GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Review
- Article
- Macrophage-derived VISTA engages with LRIG1 and hinders gut epithelial repair in colitis.Cellular & molecular immunology · 2025Article
- Microbiota-mediated mechanisms of mucosal immunity across the lifespan.Nature immunology · 2025Review
- Article
- Oxygen-Mediated Molecular Mechanisms Involved in Intestinal Ischemia and Reperfusion Injury.International journal of molecular sciences · 2025Review
- Excretory/secretory products from Hymenolepis nana adult worms alleviate ulcerative colitis in mice via tuft/IL-13 signaling pathway.Parasites & vectors · 2025Article
- Inflammatory bowel disease risk gene C1ORF106 regulates actin dynamics in intestinal epithelial cells.bioRxiv : the preprint server for biology · 2025Article
- Modulation of β-Catenin promotes WNT expression in macrophages and mitigates intestinal injury.Cell communication and signaling : CCS · 2025Article
- Tofacitinib and budesonide treatment affect stemness and chemokine release in IBD patient-derived colonoids.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Patients with one of the many chronic inflammatory disorders broadly classified as inflammatory bowel disease (IBD) now have a diverse set of immunomodulatory therapies at their disposal. Despite these recent medical advances, complete sustained remission of disease remains elusive for most patients. The full healing of the damaged intestinal mucosa is the primary goal of all therapies. Achieving this requires not just a reduction of the aberrant immunological response, but also wound healing of the epithelium. No currently approved therapy directly targets the epithelium. Epithelial repair is compromised in IBD and normally facilitates re-establishment of the homeostatic barrier between the host and the microbiome. In this review, we summarize the evidence that epithelial wound healing represents an important yet underdeveloped therapeutic modality for IBD. We highlight 3 general approaches that are promising for developing a new class of epithelium-targeted therapies: epithelial stem cells, cytokines, and microbiome engineering. We also provide a frank discussion of some of the challenges that must be overcome for epithelial repair to be therapeutically leveraged. A concerted approach by the field to develop new therapies targeting epithelial wound healing will offer patients a game-changing, complementary class of medications and could dramatically improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.